ExxonMobil walks away with almost three times Guyana’s debt without being audited
ExxonMobil has recovered $55B in expenses from Guyana's oil, per CEO Darren Woods. Guyana has audited $28.5B, leaving $26.5B unaudited, nearly triple its national debt. Past audits found $214M and $65.1M in overcharges. Guyana is reviewing a third audit report, delayed by the Guyana Revenue Authority. Critics demand better oversight of cost recovery.
How this was made

The 30-second read
Why it matters
The disclosed $26.5B of unaudited expenses raises questions about over‑billing and could lead to significant adjustments to Exxon’s financial statements.
Market read
The audit issue introduces a material risk to Exxon’s earnings and may affect broader oil‑sector valuations.
What to watch
The audit timeline delays and possible legal challenges could extend the resolution period, reducing immediate financial impact.
Background
ExxonMobil's long‑term production sharing agreement with Guyana includes cost‑recovery mechanisms that allow the company to recoup expenses from oil revenues.
Ticker impact
ExxonMobil faces a pending audit of $26.5B in expenses in Guyana's Stabroek Block, raising risk of cost recovery disputes and potential financial adjustments.
Downside pressure on XOM, potential 2‑4% decline if audit findings are adverse.
Large unaudited expense figure and government intent to enforce repayment create material financial risk.
Market effects
Highlights regulatory and cost‑recovery scrutiny in the oil & gas sector, potentially prompting other producers to review similar contracts.
May affect investor sentiment toward Guyana's oil assets and related regional equities.
Potentially influences global energy supply expectations if cost recovery terms tighten.
Counterpoint
Exxon could negotiate a settlement that limits cash outflows, mitigating share price impact.
Key entities
- CompanyExxonMobil
U.S. oil major operating the Stabroek Block in Guyana.
- Government AgencyGuyana Revenue Authority
Responsible for auditing Exxon’s expenses under the PSA.





